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Abstract
Background: Patients who undergo allogeneic stem cell transplantation and subsequent radiation therapy
uncommonly develop graft-versus-host disease within the irradiated area. We quantified the incidence of this
complication, which is a novel contribution to the field. From 2010 to 2014, 1849 patients underwent allogeneic
stem cell transplantation, and 41 (2 %) received radiation therapy afterward. Of these, two patients (5 %) developed
graft-versus-host disease within the irradiated tissues during or immediately after radiation therapy.
Case presentation: The first patient is a 37-year-old white man who had Hodgkin lymphoma; he underwent
allogeneic stem cell transplantation from a matched unrelated donor and received radiation therapy for an
abdominal and pelvic nodal recurrence. After 28.8 Gy, he developed grade 4 gastrointestinal graft-versus-host
disease, refractory to tacrolimus and steroids, but responsive to pentostatin and photopheresis. The other patient is
a 24-year-old white man who had acute leukemia; he underwent allogeneic stem cell transplantation from a
matched related donor and received craniospinal irradiation for a central nervous system relapse. After 24 cobalt Gy
equivalent, he developed severe cutaneous graft-versus-host disease, sharply delineated within the radiation
therapy field, which was responsive to tacrolimus and methylprednisolone.
Conclusions: We conclude that graft-versus-host disease within irradiated tissues is an uncommon but potentially
serious complication that may follow radiation therapy in patients who have undergone allogeneic stem cell
transplantation. Clinicians must be aware of this complication and prepared with strategies to mitigate risk. Patients
who have undergone allogeneic stem cell transplantation represent a unique population that may offer novel
insight into the pathways involved in radiation-related inflammation.
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Background
The management of hematologic malignancies is com-
plex, often involving several types of therapies with tox-
icities that are heavily influenced by other treatments
administered. Allogeneic stem cell transplantation (ASCT)
is an important form of treatment for some hematologic
cancers. A significant cause of morbidity and mortality
after ASCT is graft-versus-host disease (GVHD), an im-
mune response mounted by donor cells against recipient
tissues. Several risk factors for GVHD have been identified
[1, 2], among them radiation therapy (RT). Our group and
others have reported rare cases of GVHD arising within
irradiated tissues in patients who have undergone ASCT
[3–5]. In this study, we aimed to assess the frequency of
this complication.
With the approval of our institutional review board,
we retrospectively reviewed records of patients who had
undergone ASCT at our institution from 1 January 2010
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to 31 December 2014. Those who had received at least
one course of RT after ASCT comprised the study popu-
lation. Disease characteristics, treatment details, and
clinical outcomes were retrieved from electronic medical
records. GVHD was defined and graded by treating phy-
sicians based on clinical and pathologic findings. The RT
plans were reviewed to determine the dose that had been
delivered to the affected organs.
During the study interval, 1849 patients underwent an
ASCT at our institution, 41 (2 %) of whom also received
at least one course of RT after ASCT. The baseline char-
acteristics of this cohort are summarized in Table 1. Of
these 41 patients, 17 (41 %) experienced acute GVHD
(four grade 1, 11 grade 2, and two grade 3); in four
cases, the diagnosis of acute GVHD was made after RT
(range 21 to 204 days after initiation of RT). In this co-
hort, nine patients (22 %) developed chronic GVHD
(one limited and eight extensive); in four cases, chronic
GVHD was diagnosed after treatment with RT (range 22
to 238 days after initiation of RT).
In two patients (5 % of the cohort), GVHD developed
during or immediately after RT within the irradiated tis-
sues. In a third case, hemorrhagic esophagitis developed
7 days after completion of craniospinal irradiation (CSI).
Although an esophageal biopsy was morphologically
suggestive of GVHD, the clinical presentation was not
consistent with this diagnosis, and the symptoms re-
solved with steroids alone. Therefore, the symptoms
were attributed to RT-induced inflammation, and this
case was not included. The two cases of GVHD follow-
ing RT are described below.
Case presentation
Case 1
An otherwise healthy 37-year-old white man had che-
morefractory classic Hodgkin lymphoma, treated with
the following regimens: (1) doxorubicin, bleomycin, vin-
blastine, and dacarbazine; (2) ifosfamide, carboplatin,
and etoposide; (3) brentuximab; (4) gemcitabine and
vinorelbine; (5) bendamustine; (6) everolimus; (7) siroli-
mus and vorinostat; (8) lenalidomide; and (9) dexa-
methasone, cytarabine, and cisplatin. He then underwent
an ASCT from a 10/10 matched unrelated donor, with a
fludarabine and melphalan conditioning regimen.
Three months after the ASCT, the disease relapsed in
his abdominal and pelvic lymph nodes. He was treated
with intensity-modulated RT to his para-aortic and pel-
vic lymph nodes, starting on day 119 after the ASCT. At
that time, no evidence of GVHD was present, and the
tacrolimus was tapered off. The plan was to treat his ab-
dominal and pelvic lymph nodes with a total dose of
39.6 Gy in 22 fractions. However, after completing 28.8
Gy in 16 fractions, he experienced severe abdominal
pain, nausea, vomiting, and copious watery diarrhea. An
Table 1 Patient, disease, and treatment characteristics
Characteristic Value or number
of patients (%)
Age at allogeneic stem cell transplantation, years
Median (range) 40 (21–69)
Sex
Male 32 (78 %)
Female 9 (22 %)
Ethnicity
White 26 (63 %)
Hispanic 10 (24 %)
Black 5 (12 %)
Diagnosis
Acute myeloid leukemia 9 (22 %)
Acute lymphocytic leukemia 7 (17 %)
Acute biphenotypic leukemia 1 (2 %)
Chronic myeloid leukemia 3 (7 %)
Chronic lymphoid leukemia 1 (2 %)
Mantle cell lymphoma 2 (5 %)
Classical Hodgkin lymphoma 7 (17 %)
Mycosis fungoides 6 (15 %)
Diffuse large B-cell lymphoma 4 (10 %)
Peripheral T-cell lymphoma 1 (2 %)
Donor
Matched unrelated donor 21 (51 %)
Matched related donor 18 (44 %)
Cord blood 2 (5 %)
Conditioning regimen
Busulfan/fludarabine 11 (27 %)
Busulfan/clofarabine 5 (12 %)
Busulfan/fludarabine/clofarabine 1 (2 %)
Fludarabine/melphalan 13 (32 %)
Fludarabine/melphalan/rituximab 1 (2 %)
Fludarabine/bendamustine/rituximab 1 (2 %)
Fludarabine/bendamustine/ibritumomab 1 (2 %)
Fludarabine/melphalan/alemtuzumab 2 (5 %)
Melphalan/thiotepa/fludarabine/cyclophosphamide 1 (2 %)
Busulfan/clofarabine/gemcitabine 4 (10 %)
Fludarabine/cyclophosphamide/2 Gy TBI 1 (2 %)
Time from ASCT to RT, days
Median (range) 299 (45–1715)
RT dose, Gy
Median (range) 23.4 (2–44)
Number of RT fractions
Median (range) 12 (1–22)
ASCT allogeneic stem cell transplantation, RT radiation therapy, TBI total
body irradiation
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endoscopy revealed an erythematous gastrointestinal mu-
cosa with superficial ulcers. Biopsies taken throughout his
gastrointestinal tract were consistent with GVHD. In his
stomach and duodenum, the mucosa showed loss of
glands, dilated glands with eosinophilic and granular deb-
ris, and increased apoptotic cells (Fig. 1). In his colon, in-
creased apoptotic cells and loss of glands were identified.
These findings led to a diagnosis of grade 4 GVHD of
the gastrointestinal tract, experienced after 28.8 Gy. His
bowel, contoured as “bowel space,” received a maximum
dose of 31.8 Gy and mean dose of 14.8 Gy. The volume
of bowel space that received ≥30 Gy was 39 cc, ≥20 Gy
was 1400 cc, and ≥10 Gy was 2450 cc. His stomach re-
ceived a maximum dose of 25 Gy and mean dose of 2.9
Gy. The volume of stomach that received ≥20 Gy was
4.3 cc and ≥10 Gy was 31 cc (Fig. 2). Initial treatment
with tacrolimus and steroids (2 mg/kg/day) had no ef-
fect, but subsequent pentostatin and photopheresis pro-
duced a good response. At last follow-up, 6 months after
RT had been stopped, his GVHD was quiescent on
photopheresis and tacrolimus, with no evidence of active
Hodgkin lymphoma in his abdomen or pelvis.
Case 2
As previously reported [4], an otherwise healthy 24-year-
old white man with relapsed Philadelphia-positive B-cell
acute lymphocytic leukemia was treated initially with
cyclophosphamide, vincristine, doxorubicin, dexametha-
sone, cytarabine, and methotrexate (hyper-CVAD) with
dasatinib. Disease relapse in his central nervous system
(CNS) and bone marrow during maintenance therapy
was salvaged with augmented hyper-CVAD and dasati-
nib, followed by a 10/10 human leukocyte antigen
(HLA)-matched related ASCT from his sister, with a bu-
sulfan and clofarabine conditioning regimen.
On day 82 after the ASCT, he presented with a head-
ache; he was diagnosed as having an isolated CNS re-
lapse and was treated with rituximab, asparaginase,
dasatinib, high-dose methotrexate, and intrathecal cytar-
abine, followed by consolidative CSI. The CSI was with
proton therapy, to a total dose of 24 cobalt Gy equiva-
lent (CGE) in 12 fractions. His brain was treated with
right and left posterior oblique beams, and his spine was
treated with three posterior-anterior beams. The CSI
was begun on day 197 after the ASCT, and no evidence
of GVHD was present at that time. The tacrolimus dose
was reduced during RT.
One month after completing CSI, he developed severe
dermatitis within the RT portals and conjunctivitis, kera-
topathy, and conjunctival ulceration. The dose delivered
to his skin had been 22 CGE [4]. A skin biopsy showed
inflammatory cell-poor interface dermatitis with vacu-
olar alterations of the basal keratinocytes and dyskerato-
tic cells, consistent with grade 2 to 3 GVHD. Treatment
with tacrolimus and methylprednisolone (2 mg/kg/day)
resulted in resolution of his cutaneous GVHD; however,
keratoconjunctivitis sicca persisted despite prednisolone
ophthalmic drops. His cutaneous GVHD returned sev-
eral months later, both within and outside the RT field.
This extensive chronic GVHD progressed despite steroids,
tacrolimus, and photopheresis, manifesting as ulcerations,
scleroderma-like changes, and chronic osteomyelitis that
necessitated bilateral above-the-knee amputations. He
died of aspiration pneumonia and respiratory failure 4.5
years after the ASCT, with no evidence of leukemia.
Conclusions
GVHD is a potentially serious complication that may
follow RT in patients who have undergone ASCT. Cases
have been reported [4–6]; however, the incidence of this
complication was unknown previously. We identified
41 sequential patients who received RT after ASCT,
two (5 %) of whom developed clinically significant GVHD
within the irradiated tissues during or immediately after
Fig. 1 a Full thickness of gastric antrum showing denuded epithelium,
loss of glands, dilated glands, and relatively few inflammatory cells in
the lamina propria. b High magnification showing dilated gastric
glands with eosinophilic granular debris and apoptotic nuclear
fragments. These findings support grade 4 graft-versus-host disease
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RT, despite delivery of relatively low doses to the affected
organs. Radiation-induced inflammation was an alterna-
tive diagnosis that was considered; however, both the
clinical and pathological findings were consistent with
GVHD. We conclude that GVHD following RT is uncom-
mon; however, this diagnosis should be considered in
patients who have undergone ASCT and who develop RT-
related side effects that are more severe than expected.
Discussion
Given the study design, conclusive demonstration of a
causal relationship between RT and GVHD is not possible.
However, GVHD developed within the irradiated tissues
during or immediately following RT, in patients who were
without evidence of GVHD previously. Furthermore, in
Case 2, cutaneous GVHD was strictly demarcated within
the irradiated area [4]. These findings strongly suggest a
causal relationship.
The small number of events in this study precludes
the identification of factors that might modify the risk of
GVHD. It is notable, however, that the doses of im-
munosuppressive agents were tapered around the time
of RT in both cases. This observation suggests that im-
munosuppressive therapy should not be reduced during
this period, even if patients are free of clinically apparent
GVHD at the time of RT.
Theoretically, RT can trigger GVHD via local cellular
damage and induction of pro-inflammatory pathways.
Multiple inflammatory mediators are activated, upregu-
lated, or released in response to ionizing radiation, such
as NF-kB, TNF-α, TGF-β, GM-CSF, COX-2, ICAM-1,
IL-1, IL-6, IL-8, IFN, c-Fos, c-Myc, c-Jun, and extracellu-
lar nucleotides [6–11]. The resulting chemotactic signals
lead to rapid recruitment of diverse leukocyte subgroups
into the irradiated area [12–14]. RT also upregulates ex-
pression of major histocompatibility complex (MHC)
class I/II antigens by cancer cells, rendering them more
sensitive to T cell recognition through antigen presenta-
tion by dendritic cells [13, 15, 16]. RT may well have
similar effects on normal tissues. For patients who have
had an ASCT, this immune stimulation may cause den-
dritic cells to present host antigens to donor T cells, pre-
disposing to the development of GVHD.
The immune response induced by ionizing radiation is
an area of fervent study, both in the laboratory and in
the clinic. Patients who have undergone ASCT represent
a unique population that may offer additional insight
into the pathways involved in radiation-related inflam-
mation. Furthermore, clearer understanding of the
mechanisms by which RT induces GVHD may enable
the development of therapeutic interventions. RT is a
highly effective form of treatment for hematologic malig-
nancies, but clinicians must be able to recognize risk fac-
tors for toxicity, including GVHD, and strive to develop
strategies to mitigate morbidity.
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